ArticleArchives of dermatological research2025
Dickkopf 1 and Neuregulin 1 as cutaneous biomarkers for dermal pigmentation activity in acquired dermal macular hyperpigmentation (ADMH): a case control study.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichen planus pigmentosus (LPP), ashy dermatosis, and Riehl's melanosis are all referred to by the general term acquired dermal macular hyperpigmentation (ADMH). These conditions are distinguished clinically by hyperpigmented macules and patches of unknown cause. Melanogenesisis regulated by multiple dermal factors secreted by fibroblasts and among them are neuregulin1 (NRG1) and dickkopf1 (DKK1). This study was designed to study NRG1 and DKK1 as cutaneous biomarkers for activity of dermal pigmentation in ADMH and to correlate their activity with acquired dermal macular hyperpigmentation area and severity index (DPASI) score. A total of 35 clinically diagnosed ADMH patients and 10 healthy controls along with 4 positive controls of melasma patients were included in the study and DPASI score was calculated using Dermlite (DL4) dermatoscope to assess the disease severity. Skin biopsy samples were taken and immunofluorescence and qPCR were performed to measure the expression of NRG1 and DKK1. A correlation of NRG1 expression, DKK1 expression with DPASI score was assessed. NRG1 expression had a linear positive correlation with DPASI score with a correlation coefficient (r = 0.97) (p < 0.001), while DKK1 showed an inverse correlation with a correlation coefficient (r=-0.69) (p < 0.001). NRG1 and DKK1 expression regulates pigmentation in ADMH and they can be used as an objective tool to assess the disease activity and probably guide therapy.
Indexed as
Identifiers
39921734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.